CAJ | 학술논문

目的利用RelB小干扰RNA (siRNA)沉默的树突状细胞(DC)预防心脏移植排斥反应.方法 RelB siRNA-DC同同种抗原特异性T细胞进行混合淋巴细胞反应,检测反应后T细胞凋亡率及CD4+ CD25+叉状头/翅膀状螺旋转录因子(Foxp3)+调节性T细胞的比率；利用小鼠心脏移植模型,于移植前输注各组DC,观察移植后小鼠心脏存活时间；苏木素-伊红(HE)染色检测排斥反应程度.结果较其他3组DC,RelB siRNA组DC刺激同种T细胞增殖能力明显减弱(P＜0.05)；但对第3方抗原T细胞无特异性低反应性(P＞0.05)；RelB siRNA-DC诱导T细胞凋亡率增加(29.21±7.55)％；诱导T细胞向CD4+ CD25+ Foxp3+ Treg分化[(65.3±12.6)％]；预先输注供体来源的RelB siRNA-DC可延长移植心存活时间(P＜0.05),降低排斥反应发生程度.结论 RelBsiRNA沉默供体来源的树突状细胞可诱导心脏移植免疫耐受.
목적 이용RelB소간우RNA (siRNA)침묵적수돌상세포(DC)예방심장이식배척반응.방법 RelB siRNA-DC동동충항원특이성T세포진행혼합림파세포반응,검측반응후T세포조망솔급CD4+ CD25+차상두/시방상라선전록인자(Foxp3)+조절성T세포적비솔；이용소서심장이식모형,우이식전수주각조DC,관찰이식후소서심장존활시간；소목소-이홍(HE)염색검측배척반응정도.결과 교기타3조DC,RelB siRNA조DC자격동충T세포증식능력명현감약(P＜0.05)；단대제3방항원T세포무특이성저반응성(P＞0.05)；RelB siRNA-DC유도T세포조망솔증가(29.21±7.55)％；유도T세포향CD4+ CD25+ Foxp3+ Treg분화[(65.3±12.6)％]；예선수주공체래원적RelB siRNA-DC가연장이식심존활시간(P＜0.05),강저배척반응발생정도.결론 RelBsiRNA침묵공체래원적수돌상세포가유도심장이식면역내수.
Objective To prevente acute rejection in cardiac transplantation by using tolerogenic dendritic cells (DC).Methods The mixed lymphocyte reaction (MLR) was performed by RelB siRNA-DC with allogenic antigen-specific T cells.The apoptosis rate of T cells and the ratio of CD4 + CD25 + Foxp3 + regulatory T cells were detected by using flow cytometry after MLR.In the murine model of cardiac transplantation,the survival time was observed after infusion of RelB siRNA-DC before transplantation.HE staining was used to examine the rejection degree in the specimens of allografts.Results Mature DC and LucR siRNA DC could stimulate the proliferation of T cells more strongly than immature DC and RelB siRNA-DC (P ＜ 0.05).The RelB siRNA-DC could induce allogeneic T cell hyporesponsiveness,but had no specific reactivity on the third kind T cells (P ＞ 0.05).RelB siRNA-DC induced T cell apoptosis [(29.21 ± 7.55)％,P ＜ 0.05] and promoted T cells differentation into CD4 + CD25 + Foxp3 + regulatory T cells [(65.3 ± 12.6)％,P ＜ 0.05].In the mouse cardiac transplantation model,infusion of donor-derived Lenti-RelB siRNA-DC could prolong the graft survival time (P ＜ 0.05) and reduce rejection occurrence.Conclusion Donor-derived RelB-siRNA-induced tolerogenic DC can significantly induce immune tolerance in vitro and in vivo.